SEC Form 4 · accession 0001708138-18-000007
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil Stahl
Officer — EVP Research and Development
Period of report
May 23, 2018
Accepted (ET)
May 25, 2018 · 4:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 23, 2018 | M | 26,736 | $30.63 | A | 58,709 | D | |
| Common Stock | May 23, 2018 | F | 15,329 | $293.68 | D | 43,380 | D | |
| Common Stock | May 24, 2018 | S | 11,407 | $295.09 | D | 31,973 | D | |
| Common Stock | holding | — | — | — | 4,660 | I | by GRAT | |
| Common Stock | holding | — | — | — | 2,317 | I | by GRAT | |
| Common Stock | holding | — | — | — | 5,673 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $30.63 | May 23, 2018 | M | 26,736 | D | — | Dec 14, 2020 | Common Stock | 26,736 | 0 | D |
Explanation of responses
- F1Represents volume-weighted average price of sales of 11,407 shares of Company stock on May 24, 2018 at prices ranging from $295.00 to $295.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 24, 2018 at each separate price.
- F2The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.